IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
about
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Clonal Hematopoiesis of Indeterminate Potential.Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.Isocitrate dehydrogenase mutations in myeloid malignancies.Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.Predicting Chemotherapy Resistance in AML.Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia.The rocky road to personalized medicine in acute myeloid leukaemia.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.Remission is good - relapse is bad.Measurement of Residual Disease in Acute Myeloid Leukemia.DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.
P2860
Q33832709-45B6DD69-CEAD-4568-9961-896585C28F8EQ34527941-FB9E8026-D6D2-46D1-BB6B-53ABEE41AF4EQ36849666-E8A4BE23-2393-498D-983A-C6F01E50840DQ37338371-DD41E1E6-4FF4-47F0-9326-0F21BE9885DDQ37625630-1A657A4B-2782-43F7-B5F7-7802BDF67846Q38902497-049A1D67-58FC-449C-9355-D096A1F19874Q39233284-A8C9B6F9-023B-454B-AD36-93EAC70245BAQ39264807-E1448E98-1072-4122-88FA-6191A4A35EF2Q40497621-6A1DCB74-D568-4E45-8060-99407A4B7467Q41007712-FEEF41B3-3D8C-4DEF-B543-6FBC4912EA13Q47561008-3691FAC9-862D-43C4-A51D-0F94B862BA14Q47670541-4F5EFEEE-E2C3-4A30-B1DD-3F7A8F036665Q48272510-DB06C9BF-FAB6-48D2-A78E-DB0BEE91DCE8Q49305200-B288FDAE-2F90-4D9A-9D56-46597E4F5E81Q50075132-1801F817-943A-45A6-9E57-D6EB566322C9Q50567870-CBB5ED8B-41A3-4985-859B-7A879F8E432CQ52689074-F874BA86-7AA4-44B9-91C5-F412E6E159EAQ55279705-34728504-2550-4686-9707-9272CC927C4C
P2860
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@ast
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@en
type
label
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@ast
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@en
prefLabel
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@ast
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@en
P2093
P2860
P50
P356
P1433
P1476
IDH1/2 but not DNMT3A mutation ...... e Leukemia French Association.
@en
P2093
Aline Renneville
Bérengère Gruson
Christophe Roumier
Claude Gardin
Céline Berthon
Delphine Lebon
Hervé Dombret
Houria Debarri
Marie-Lorraine Chretien
Meyling Cheok
P2860
P304
42345-42353
P356
10.18632/ONCOTARGET.5645
P407
P577
2015-10-13T00:00:00Z